{
  "attach_pages": "6",
  "attach_size": "1067",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201803261110375859_1.pdf?1522062150000.pdf",
  "company_code": "10000082",
  "eitime": "2018-03-26 11:02:49",
  "extend": {},
  "info_code": "AP201803261110375859",
  "language": "0",
  "notice_date": "2018-03-26 00:00:00",
  "notice_title": "主业内生增速符合预期，合、联营企业投资收益拉低扣非业绩",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "李敬雷",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "1042",
          "publishName": "医药商业"
        }
      ],
      "short_name": "上海医药",
      "short_name_ch": "上海医药",
      "short_name_cht": "上海醫藥",
      "short_name_en": "SHANGHAI PHARMA",
      "stock": "601607"
    }
  ],
  "short_name": "上海医药",
  "source_sample_name": "国金证券",
  "star": "5"
}